HopeStage
Back to all studies
CompletedNCT00854919

Antipsychotic add-on therapy or exposure practice for OCD not helped by SSRIs

About this title

Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder

Read the official source — NCT00854919
Medication studyAges 20–50Japan
The study in practice

Understand this study

Who was this study for?

Listed age limits: 20 years to 50 years.

Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2006
Recruitment status
Completed
Enrollment listed in the registry
Not clearly listed
Sponsor
Osaka City University
Sponsor type
University
Study type
Drug
Intervention type
Behavioural, Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Japan
Age range
From 20 Years to 50 Years
Official registry ID
NCT00854919
Official title
Show the full official title

An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Osaka

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Osaka City University, a university.

Did this study involve medication?

Yes. The study involved medication, including atypical antipsychotic drug.

Who was this study for?

Listed age limits: 20 years to 50 years.

Want to explore more studies?

Explore studies